Mylan N.V. (MYL) Getting Somewhat Favorable Media Coverage, Study Finds
News articles about Mylan N.V. (NASDAQ:MYL) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan N.V. earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.3809814655667 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Mylan N.V. (NASDAQ:MYL) traded up $0.09 during midday trading on Monday, reaching $37.59. 3,378,000 shares of the company were exchanged, compared to its average volume of 5,953,087. The company has a market cap of $20,160.00, a price-to-earnings ratio of 8.00, a PEG ratio of 2.06 and a beta of 1.38. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). The business had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. Mylan N.V. had a net margin of 7.28% and a return on equity of 20.63%. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.38 EPS. analysts predict that Mylan N.V. will post 4.56 EPS for the current year.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.